Abstract Claims Description Full Text

Abstract

The invention concerns a compound of formula (I) wherein: R1 is of the formula --NHC(=O)(1-4C)alkyl, --NHS(O)n (1-4C)alkyl wherein n is 0, 1 or 2 or R1 is hydroxy; R2 and R3 are independently hydrogen or fluoro; R4 is hydrogen, methyl, ethyl or oxo; R5 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl or of the formula R6 (CH2)m -- wherein either m is 1-4 and R6 is, for example, trifluoromethyl, difluoromethyl, fluoromethyl, (1-4C)alkoxy, (1-4C)alkyl S(O)p -- wherein p is 0, 1 or 2, (1-6C)alkanoyloxy, di-(N-(1-4C)alkyl)amino, N-((1-4C)alkyl)(1-4C)alkanoylamino, cyano, carboxy, (1-4C)alkoxycarbonyl, carbamoyl, di-(N-(1-4C)alkyl)carbamoyl, N-((1-4C)alkyl)(1-4C)alkanesulphonamido, N1 -((1-4C)alkyl)-di-(N3 -(1-4C)alkyl)ureido, or of the formula --OC(=O)NR7 (R8) or --N(R9)SO2 NR7 (R8) wherein R7 and R8 are independently hydrogen or (1-4C)alkyl and R9 is (1-4C)alkyl; or m is 2-4 and R6 is, for example, hydroxy, (1-4C)alkanoylamino, amino, (1-4C)alkylamino, (1-4C)alkanesulphonamido, ureido, di-(N3 -(1-4C)alkyl)ureido or of the formula --NHSO2 NR7 (R8); and pharmaceutically-acceptable salts thereof; processes for their preparation; pharmaceutical compositions containing them and their use as antibacterial agents.

Other References

• "Stereochemistry of Carbon Compounds" by Ernest L.Eliel,pp. 47-54, 1962
• Andes et al., Pharmacodynamic Activity of an Oxazolidinone in an Animal Infection Model, Abstract F233, Abstract of the 36th ICACC, 1996, p. 140
• Ashtekar et al., Oxazolidinones, A New Class of Synthetic Antituberculosis Agent, Diagn. Microbiol. Infect. Dis., 1991, 14(6), pp. 465-471
• Barbachyn et al., Identification of a Novel Oxazolidinone (U-100480) with Potent Antimycobacterial Activity., J. Med. Chem., 1996, vol. 39, pp. 680-685
• Barbachyn et al., Synthesis and Antibacterial Activity of New Tropone-Substituted . . . Substitution on In Vivo Activity, Bioorganic & Medical Chemistry Letters, vol. 6, No. 9, 1996, pp. 1009-1014
• Barbachyn et al., Synthesis and Antibacterial Activity of New Tropone-Substituted . . . Tropone Substition Pattern, Bioorganic & Medical Chemistry Letters, vol. 6, No. 9, 1996, pp. 1003-1008
• Barry, In Vitro Evaluation of DuP 105 and DuP 721, Two New Oxazolidinone Antimicrobial Agents, Antimicrobial Agents and Chemotheraphy, Jan. 1988, 32(1), pp. 150-152
• Borthwick et al., 5-(Acetamidomethyl)-3-Aryldihydrofuran-2-Ones, . . . Two New Classes of Antibacterial Agents, Med. Chem. Res., 1996, pp. 22-27
• Brickner et al., Sythesis and Antibacterial Activity of U-100592 . . . Multidrug-Resistant Gram-Positive Bacterial Infections., J. Med. Chem. 1996k vol. 39, 673-679
• Brickner, Oxazolidinone Antibacterial Agents, Current Pharmaceutical Design, 1996, vol. 2, pp. 175-194
• Brumfitt et al., Antibacterial Oxazolidinones In vitro Activity of a New Analogue, E3709, Diagn. Microbiol. Infect. Dis., 1992, vol. 15, pp. 621-625
• Brumfitt et al., In-vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazoldinones, Journal of Antimicrobial chemotherapy, 1988, 21(6), pp. 711-720
• Brumfitt et al., Variation in response of Gram-positive cocci to the combination of DuP 721 and ciprofloxacin, J. Anticmicrob. Chemother., 1989, 24(3) pp. 465-466
• Buysse et al. Mutation of the AcrAB Antibiotic Efflux Pump in Esherichia coli Confers Susceptibility to Exazolidinone Antibiotics, Abstract C42, Abstract of the 36th ICACC, 1996, p. 41
• Daly et al., Activity and mechanism of action of DuP 105 and DuP 721, new oxaxolidinone compounds, Journal of Antimicrobial Chemotherapy, 1988, 21(6), pp. 721-730
• Denis et al., 5-Aryl-.cndot.,.cndot. Butenolide, A New Class of Antibacterial Derived . . . N-Aryl Oxazolidinone Dup 721, Bioorganic and Medicinal Chemistry Letters, 1994, vol. 4, No. 16, pp. 1925-1930
• Dostert et al., Structural Modifications in Oxazolidinone Series Leading to Type A or B Selective Monoamine Oxidase Inhibitors, Int. Congress Series. Excerpta Medica, 1982, pp. 197-208
• Eliopoulos et al., In Vitro Activities of New Oxazolidinone Antimicrobial Agents against Enterococci, Antimicrobial Agents and Chemotheraphy, Jul. 1996, 40(7), pp. 1745-1747
• Eustice et al., An Automated Pulse Labelling Method for Structure-Activity Relationship Studies with Antibacterial Oxazolidinones, Durgs. Exptl. Clin. Res., 1990, 16(4), pp. 149-155
• Eustice et al., Mechanism of Action of DuP 721: Inhibition of an Early Event during Initiation of Protein Synthesis, Antimicrobial Agents and Chemotheraphy, Aug, 1988, 32(8), pp. 1218-1222
• Eustice et al., The Mechanism of Action of DuP 721, A New Antibacterial Agent: Effects on Micromolecular Synthesis, Biochem. & Biophys. Res. Commun., Feb. 15, 1988, 150(3), pp. 965-971
• Ford et al., In Vivo Activities of U-100592 and U-100766, . . . against Experimental Bacterial Infections, Antimicrobial Agents and Chemotheraphy, Jun. 1996, 40(6). pp. 1508-1513
• Grega et al., Regioselective Metalation of Fluoroanilines. An Application to the Synthesis of Fluorinated Oxazolidinone Antibacterial Aents; J. Org. Chem., 1995, 60. pp. 5255-5261
• Gregory et al., Antibacterials, Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines.1. The "B" Group, J. Med. Chem., 1989, 32(8), pp. 1673-1681
• Gregory et al., Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines.2. The "A" Group, J. Med. Chem., 1990, vol. 33, pp. 2569-2578
• Hutchinson et al., Piperazinyl Oxqzolidinones: Structure Activity Relationships of a New Class of Oxazolidinone Antibacterial Agents, ICAAC (Interscience Congress of Antimicrobial Agents and Chemotherapy) meeting abstracts: Sep. 17-20th 1995, pp. 8-14
• Jones et al., In Vitro Antimicrobial Activities and Spectra of U-100592 and U-100766, . . . Oxazolidinones, Antimicrobial Agents and Chemotheraphy, Mar. 1996, 40(3), pp. 720-726
• Jorgensen et al., In Vitro Activities of the Oxazolidinone Antibiotics U-100592 . . . Negative Staphylococcus Species, Antimicrobial Agents and Chemotheraphy, Feb. 1997, 41(2), pp. 465-467
• Kaatz et al., In Vitro Activities of Oxazolidinone Compounds U100592 . . . Staphylococcus epidermidis, Antimicrobial Agents and Chemotheraphy, Mar. 1996, 40(3), pp. 799-801
• Lin et al., Oxazolidiones Block Translation Initiation by Binding to Ribosomes, Abstract C101, Abstract of the 36th ICACC, 1996, p. 52
• Lin et al., The Oxazolidinone Eperezolid Binds to the 50S Ribosomal Subunit . . . of Chloramphenicol and Linocomycin, Antimicrobial Agents and Chemotheraphy, Oct. 1997, 41(10), pp. 2127-2131
• Lizondo et al., Linezolid, Oxazolidinone Antibacterial, Drugs of the Future, 1996, 21(11), pp. 1116-1123
• Lund et al., Hypersegmented Megakaryocytes and Megakaryocytes with Multiple . . . an Oxazolidinone Antibiotic, Toxicologic Pahtyology, 25(4), pp. 339-343
• Maple et al., Comparative in-vitro activity of vancomycin, teicoplanin, . . . methicillin and gentamicin resistant Staphyloccus aureus, Journal of Antimicrobial Chemotherapy, 1989, 23(4), pp. 517-525
• Mason et al., In Vitro Activities of Oxazolidinones U-100592 and U-100766 . . . Strains of Streptocossu pneumoniae, Antimicrobial Agents and Chemotheraphy, Apr., 1996, 40(4), pp. 1039-1040
• Mini et al., Comparative in Vitro Activity of the New Oxazolidinones DuP 721 and DuP 105 against Staphylococci and Streptococci, Eur. J. Clin. Microbiol. Infect. Dis., 1989, 8(3), pp. 356-360
• Mulazimoglu et al., In Vitro Activities of Two Novel . . . Staphylococcus aureus and Staphylococcus epidermidis, Antimicrobial Agents and Chemotheraphy, Oct. 1996, 40(10), pp. 2428-2430
• Neu et al., In Vitro Activities of Two Oxazolidinone Antimicrobial Agents, DuP 721 and DuP 105, Antimicrobial Agents and Chemotheraphy, Apr. 1988, 32(4), pp. 580-583
• Park et al., Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 4. Multiply-Substituted Aryl Derivatives, J. Med. Chem., 1992, vol. 35, pp. 1156-1165
• Ranaldi et al., Transport of the Antibacterial Agent Oxazolidin-2-One and . . . (MDCK) Epithelial Cell Lines, Antimicrobial Agents and Chemotheraphy, Mar. 1996, 40(3), pp. 652-658
• Schaadt et al., Serum Inhibitory Titers and Serum Bactericidal for Human . . . Eperezolid and Linezolid, Diagn. Microbiol. Infect. Dis., 1997, 28(4), pp. 201-204
• Schaus et al., Dynamic Kinetic Resolution . . . Aryl Oxazolidinone Antibacterial Agents, Tetrahedron Letters, 1996, 37(44), pp. 7937-7940
• Scholl et al., Micellar electrokinetic chromatograpny as a generalized alternative . . . of a class of investigational antibacterial drugs., Journal of Chromoatography B, 1997, 695(1), pp. 147-156
• Seneci, et al., Synthesis and Antimicrobial Activity of Oxazolidin-2-ones and Related Heterocycles, J. Chem. Soc. Perkin Trans., 1994, vol. 16, pp. 24352351
• Shinabarger et al., Mechanism of Action of Oxazolidinones: Effects of Linezolid and Eperezolid on Translation Reactions, Antimicrobial Agents and Chemotheraphy, Oct. 1997, 41(10), pp. 2132-2136
• Silverman et al., The Oxazlidinone Antibacterial Agent DuP 105 Does not Act on Cell Wall Biosynthesis or on a B-Lactamase, Biochemical and Biophysical Research Communications, Sep. 15, 1993, 195(2), pp. 1077-1080
• Slee et al., Oxazolidinones, A New Class of Synthetic Antibacterial Agents: In Vitro of DuP 105 and DuP 721, Antimicrobial Agents and Chemotheraphy, Nov. 1987, pp. 1791-1797
• Spangler et al., Activities of RPR 106972 (a New Oral Streptogramin), . . . 203 Penicillin-Susceptible and -Resistant Pneumococci, Antimicrobial Agents and Chemotherapy, Feb. 1996, pp. 481-484
• Spangler et al., Activities of RPR 106972 (a New Oral Streptogramin), . . . -Resistant pneumocci, Antimicrobial Agents and Chemotheraphy, Feb. 1996, 40(2), pp. 481-484
• Takagi et al., Safety Pharmacology Evaluation of the Oxazolidinone, U-100766, Abstract 564, Society of Toxicology (SOT) Annual Meeting, 1996, pp. 110
• Wang et al., Chiral Synthesis of Dup 721, A New Antibacterial Agent, Tetrahedron, 1989, 45(5), pp. 1323-1326
• Worth et al., Quality Guidelines for Amoxicillin, . . . Various National Committee for Clinical Laboratory Standards Susceptibility Testing Methods, Diagn. Microbiol. Infect. Dis, 1996, 24(2), pp. 87-91
• Zurenko et al., In Vitro Activities of U-100592 and U-100766, Novel Oxazolidinone Antibacterial Agents, Antimicrobial Agents and Chemotheraphy, Apr. 1996, 40(4), pp. 839-845
• Zurenko et al., Oxazolidinone antibacterial agents: development of the clinical candidates eperezolid and linezolid, Exp. Opin. Invest. Drugs, vol. 6, No. 2, pp. 151-15